

Sean J Pittock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5334463/publications.pdf>

Version: 2024-02-01

289
papers

30,840
citations

5268

83
h-index

5120

166
g-index

295
all docs

295
docs citations

295
times ranked

12072
citing authors

#	ARTICLE	IF	CITATIONS
1	A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet, The, 2004, 364, 2106-2112.	13.7	2,839
2	IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. Journal of Experimental Medicine, 2005, 202, 473-477.	8.5	1,998
3	The spectrum of neuromyelitis optica. Lancet Neurology, The, 2007, 6, 805-815.	10.2	1,897
4	Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain, 2007, 130, 1194-1205.	7.6	650
5	Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression. Archives of Neurology, 2006, 63, 964.	4.5	643
6	Brain Abnormalities in Neuromyelitis Optica. Archives of Neurology, 2006, 63, 390.	4.5	637
7	Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Annals of Neurology, 2006, 59, 566-569.	5.3	548
8	Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. New England Journal of Medicine, 2019, 381, 614-625.	27.0	536
9	Neuromyelitis Optica and Non-Organ-Specific Autoimmunity. Archives of Neurology, 2008, 65, 78-83.	4.5	497
10	Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Annals of Neurology, 2018, 83, 166-177.	5.3	479
11	Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis. Archives of Neurology, 2006, 63, 197.	4.5	470
12	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, The, 2019, 394, 1352-1363.	13.7	433
13	Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy. JAMA Neurology, 2016, 73, 1297.	9.0	383
14	Glial fibrillary acidic protein immunoglobulin <scp>G</scp> as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Annals of Neurology, 2017, 81, 298-309.	5.3	366
15	Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurology, The, 2013, 12, 554-562.	10.2	335
16	Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. Journal of Experimental Medicine, 2008, 205, 2473-2481.	8.5	330
17	Autoimmune Epilepsy. Archives of Neurology, 2012, 69, 582.	4.5	324
18	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain, 2010, 133, 2626-2634.	7.6	316

#	ARTICLE	IF	CITATIONS
19	Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. <i>Annals of Neurology</i> , 2004, 56, 715-719.	5.3	303
20	Amphiphysin autoimmunity: Paraneoplastic accompaniments. <i>Annals of Neurology</i> , 2005, 58, 96-107.	5.3	297
21	Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. <i>American Journal of Ophthalmology</i> , 2018, 195, 8-15.	3.3	295
22	Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments. <i>Annals of Neurology</i> , 2003, 53, 580-587.	5.3	286
23	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgGâ€“Associated Disorders. <i>JAMA Neurology</i> , 2018, 75, 1355.	9.0	286
24	Treatment of Neuromyelitis Optica With Mycophenolate Mofetil. <i>Archives of Neurology</i> , 2009, 66, 1128-33.	4.5	283
25	Epidemiology of aquaporinâ€“4 autoimmunity and neuromyelitis optica spectrum. <i>Annals of Neurology</i> , 2016, 79, 775-783.	5.3	263
26	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	10.2	261
27	DPPX potassium channel antibody. <i>Neurology</i> , 2014, 83, 1797-1803.	1.1	255
28	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. <i>JAMA Neurology</i> , 2019, 76, 301.	9.0	243
29	Expanded phenotypes and outcomes among 256 <scp>LGI</scp>1/<scp>CASPR</scp>2â€“<scp>I</scp>g<scp>G</scp>â€“positive patients. <i>Annals of Neurology</i> , 2017, 82, 79-92.	5.3	242
30	Stiff-Man Syndrome and Variants. <i>Archives of Neurology</i> , 2012, 69, 230.	4.5	236
31	Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 757-768.	1.9	227
32	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. <i>Frontiers in Neurology</i> , 2020, 11, 501.	2.4	216
33	Glutamic Acid Decarboxylase Autoimmunity With Brainstem, Extrapyramidal, and Spinal Cord Dysfunction. <i>Mayo Clinic Proceedings</i> , 2006, 81, 1207-1214.	3.0	212
34	Short Myelitis Lesions in Aquaporin-4-IgGâ€“Positive Neuromyelitis Optica Spectrum Disorders. <i>JAMA Neurology</i> , 2015, 72, 81.	9.0	209
35	Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. <i>Neurology</i> , 2013, 81, 1197-1204.	1.1	206
36	The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. <i>Acta Neuropathologica</i> , 2020, 139, 875-892.	7.7	205

#	ARTICLE	IF	CITATIONS
37	Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. <i>Annals of Neurology</i> , 2004, 56, 303-306.	5.3	197
38	Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. <i>Annals of the New York Academy of Sciences</i> , 2016, 1366, 20-39.	3.8	184
39	International multicenter examination of MOG antibody assays. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	180
40	Aquaporin-4 Autoantibodies in a Paraneoplastic Context. <i>Archives of Neurology</i> , 2008, 65, 629-32.	4.5	177
41	Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination. <i>Archives of Neurology</i> , 2011, 68, 870.	4.5	173
42	Adult-Onset Opsoclonus-Myoclonus Syndrome. <i>Archives of Neurology</i> , 2012, 69, 1598.	4.5	172
43	IgLON5 antibody. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e385.	6.0	172
44	Insights From LGI1 and CASPR2 Potassium Channel Complex Autoantibody Subtyping. <i>JAMA Neurology</i> , 2013, 70, 229.	9.0	170
45	Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis. <i>New England Journal of Medicine</i> , 2019, 381, 47-54.	27.0	169
46	Intractable vomiting as the initial presentation of neuromyelitis optica. <i>Annals of Neurology</i> , 2010, 68, 757-761.	5.3	168
47	Voltage-Gated Potassium Channel Autoimmunity Mimicking Creutzfeldt-Jakob Disease. <i>Archives of Neurology</i> , 2008, 65, 1341-6.	4.5	166
48	Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e161.	6.0	163
49	Autoimmune Dementia: Clinical Course and Predictors of Immunotherapy Response. <i>Mayo Clinic Proceedings</i> , 2010, 85, 881-897.	3.0	158
50	Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). <i>Brain</i> , 2017, 140, 2415-2425.	7.6	158
51	Chronic pain as a manifestation of potassium channel-complex autoimmunity. <i>Neurology</i> , 2012, 79, 1136-1144.	1.1	154
52	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. <i>Annals of Neurology</i> , 2016, 79, 437-447.	5.3	148
53	LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 526-534.	1.9	146
54	Ganglionic Acetylcholine Receptor Autoantibody. <i>Archives of Neurology</i> , 2009, 66, 735-41.	4.5	145

#	ARTICLE	IF	CITATIONS
55	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. <i>Neurology</i> , 2020, 95, e111-e120.	1.1	140
56	Paraneoplastic encephalomyelopathies: pathology and mechanisms. <i>Acta Neuropathologica</i> , 2011, 122, 381-400.	7.7	138
57	Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1â€‘year. <i>Journal of Neuroimmunology</i> , 2018, 321, 157-163.	2.3	136
58	A multicenter comparison of MOG-IgG cell-based assays. <i>Neurology</i> , 2019, 92, e1250-e1255.	1.1	135
59	Positron Emission Tomographyâ€‘Computed Tomography in Paraneoplastic Neurologic Disorders. <i>Archives of Neurology</i> , 2010, 67, 322.	4.5	131
60	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. <i>Brain</i> , 2019, 142, 1310-1323.	7.6	131
61	Area postrema syndrome. <i>Neurology</i> , 2018, 91, e1642-e1651.	1.1	129
62	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. <i>JAMA Neurology</i> , 2021, 78, 741.	9.0	124
63	Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. <i>Muscle and Nerve</i> , 2009, 39, 87-90.	2.2	123
64	Predictive models in the diagnosis and treatment of autoimmune epilepsy. <i>Epilepsia</i> , 2017, 58, 1181-1189.	5.1	120
65	Quality of Life Is Favorable for Most Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2004, 61, 679.	4.5	116
66	Clinical utility of testing AQP4-IgG in CSF. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e231.	6.0	113
67	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	2.0	110
68	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. <i>JAMA Neurology</i> , 2020, 77, 1420.	9.0	109
69	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. <i>Ophthalmology</i> , 2018, 125, 1628-1637.	5.2	108
70	Prediction of Neuromyelitis Optica Attack Severity by Quantitation of Complement-Mediated Injury to Aquaporin-4â€‘Expressing Cells. <i>Archives of Neurology</i> , 2009, 66, 1164-7.	4.5	106
71	Evaluation of aquaporinâ€‘4 antibody assays. <i>Clinical and Experimental Neuroimmunology</i> , 2014, 5, 290-303.	1.0	106
72	Randomized Placeboâ€‘Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. <i>Annals of Neurology</i> , 2020, 87, 313-323.	5.3	106

#	ARTICLE	IF	CITATIONS
73	Neuromyelitis optica: Changing concepts. <i>Journal of Neuroimmunology</i> , 2007, 187, 126-138.	2.3	104
74	Autoimmune chorea in adults. <i>Neurology</i> , 2013, 80, 1133-1144.	1.1	104
75	Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4â€“IgG in Patients in the Optic Neuritis Treatment Trial. <i>JAMA Ophthalmology</i> , 2018, 136, 419.	2.5	104
76	Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 150-152.	0.9	97
77	Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. <i>Movement Disorders</i> , 2004, 19, 1482-1485.	3.9	96
78	The Pathology of MS. <i>Neurologist</i> , 2007, 13, 45-56.	0.7	95
79	Neurologic autoimmunity and immune checkpoint inhibitors. <i>Neurology</i> , 2020, 95, e2442-e2452.	1.1	94
80	Serologic Profiles Aiding the Diagnosis of Autoimmune Gastrointestinal Dysmotility. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 988-992.	4.4	93
81	Relapses and disability accumulation in progressive multiple sclerosis. <i>Neurology</i> , 2015, 84, 81-88.	1.1	92
82	Effects of Age and Sex on Aquaporin-4 Autoimmunity. <i>Archives of Neurology</i> , 2012, 69, 1039-43.	4.5	91
83	Diagnosis of Neuromyelitis Spectrum Disorders. <i>Archives of Neurology</i> , 2009, 66, 1134-8.	4.5	87
84	Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. <i>Neurology</i> , 2015, 85, 722-729.	1.1	86
85	Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults. <i>JAMA Neurology</i> , 2015, 72, 1304.	9.0	86
86	Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. <i>Neurology</i> , 2018, 90, e103-e110.	1.1	86
87	Paraneoplastic Jaw Dystonia and Laryngospasm With Antineuronal Nuclear Autoantibody Type 2 (Anti-Ri). <i>Archives of Neurology</i> , 2010, 67, 1109-15.	4.5	84
88	Clinical spectrum of high-titre GAD65 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 645-654.	1.9	84
89	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	84
90	P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. <i>Muscle and Nerve</i> , 2016, 54, 220-227.	2.2	83

#	ARTICLE	IF	CITATIONS
91	The Oxfordshire Community Stroke Project classification: Correlation with imaging, associated complications, and prediction of outcome in acute ischemic stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2003, 12, 1-7.	1.6	79
92	Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. <i>JAMA Neurology</i> , 2020, 77, 937.	9.0	78
93	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. <i>Neurology</i> , 2021, 97, e1097-e1109.	1.1	77
94	Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. <i>Lancet Neurology</i> , The, 2014, 13, 795-806.	10.2	76
95	Metabotropic glutamate receptor type 1 autoimmunity. <i>Neurology</i> , 2016, 86, 1009-1013.	1.1	76
96	Seroprevalence of Aquaporin-4 IgG in a Northern California Population Representative Cohort of Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 1433.	9.0	73
97	Microtubule-associated protein 1<scp>B</scp>: Novel paraneoplastic biomarker. <i>Annals of Neurology</i> , 2017, 81, 266-277.	5.3	73
98	Neuromyelitis Optica IgG Status in Acute Partial Transverse Myelitis. <i>Archives of Neurology</i> , 2006, 63, 1398.	4.5	72
99	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021, 89, 895-910.	5.3	72
100	Autoimmune myelopathy associated with collapsin responseâ€mediator proteinâ€5 immunoglobulin G. <i>Annals of Neurology</i> , 2008, 63, 531-534.	5.3	69
101	Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 377-403.	1.8	69
102	Autoimmune Aquaporin-4 Myopathy in Neuromyelitis Optica Spectrum. <i>JAMA Neurology</i> , 2014, 71, 1025.	9.0	68
103	Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. <i>Journal of Neuroimmunology</i> , 2018, 323, 62-72.	2.3	68
104	Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. <i>Journal of Autoimmunity</i> , 2013, 40, 21-27.	6.5	67
105	Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. <i>Neurology</i> , 2019, 93, e1732-e1741.	1.1	67
106	Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 897-907.	1.9	66
107	Childhood Onset of Stiff-Man Syndrome. <i>JAMA Neurology</i> , 2013, 70, 1531.	9.0	65
108	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. <i>Multiple Sclerosis Journal</i> , 2021, 27, 303-308.	3.0	64

#	ARTICLE	IF	CITATIONS
109	Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. Multiple Sclerosis Journal, 2016, 22, 862-872.	3.0	63
110	Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e438.	6.0	63
111	Neural Autoantibody Clusters Aid Diagnosis of Cancer. Clinical Cancer Research, 2014, 20, 3862-3869.	7.0	62
112	Inflammatory transverse myelitis: evolving concepts. Current Opinion in Neurology, 2006, 19, 362-368.	3.6	61
113	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 2016, 263, 140-149.	3.6	60
114	Autoimmune Encephalitis in the ICU: Analysis of Phenotypes, Serologic Findings, and Outcomes. Neurocritical Care, 2016, 24, 240-250.	2.4	60
115	Optic neuritis in the era of biomarkers. Survey of Ophthalmology, 2020, 65, 12-17.	4.0	60
116	Neural Autoantibody Profile of Primary Achalasia. Digestive Diseases and Sciences, 2010, 55, 307-311.	2.3	59
117	Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials. Nature Reviews Neurology, 2021, 17, 759-773.	10.1	57
118	Neuronal Voltage-Gated Potassium Channel Complex Autoimmunity in Children. Pediatric Neurology, 2011, 44, 275-281.	2.1	56
119	Optical coherence tomography is highly sensitive in detecting prior optic neuritis. Neurology, 2019, 92, e527-e535.	1.1	56
120	Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients. JAMA Neurology, 2020, 77, 257.	9.0	56
121	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e343.	6.0	55
122	Long-term Safety and Efficacy of Eculizumab in Aquaporin-4-IgG-Positive NMOSD. Annals of Neurology, 2021, 89, 1088-1098.	5.3	55
123	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 384-390.	1.9	55
124	Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis. Archives of Neurology, 2006, 63, 611.	4.5	54
125	The neurologic significance of celiac disease biomarkers. Neurology, 2014, 83, 1789-1796.	1.1	54
126	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 488-490.	1.9	54

#	ARTICLE	IF	CITATIONS
127	Autoimmune Epilepsy. <i>Seminars in Neurology</i> , 2015, 35, 245-258.	1.4	53
128	Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. <i>Acta Neuropathologica</i> , 2017, 133, 597-612.	7.7	53
129	Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 218-225.	1.9	53
130	LGI1 and CASPR2 neurological autoimmunity in children. <i>Annals of Neurology</i> , 2018, 84, 473-480.	5.3	53
131	Phosphodiesterase 10A IgG. <i>Neurology</i> , 2019, 93, e815-e822.	1.1	52
132	Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder. <i>JAMA Neurology</i> , 2020, 77, 1575.	9.0	52
133	Aquaporin 4 IgG Serostatus and Outcome in Recurrent Longitudinally Extensive Transverse Myelitis. <i>JAMA Neurology</i> , 2014, 71, 48.	9.0	51
134	Paraneoplastic Neuromyelitis Optica Spectrum Disorder Associated With Metastatic Carcinoid Expressing Aquaporin-4. <i>JAMA Neurology</i> , 2014, 71, 495.	9.0	51
135	Paraneoplastic neuronal intermediate filament autoimmunity. <i>Neurology</i> , 2018, 91, e1677-e1689.	1.1	50
136	Intractable Nausea and Vomiting From Autoantibodies Against a Brain Water Channel. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 240-245.	4.4	49
137	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. <i>Neurology</i> , 2015, 84, 148-158.	1.1	49
138	Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1021-1026.	1.9	49
139	An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. <i>Lancet Neurology</i> , The, 2010, 9, 55-66.	10.2	48
140	Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. <i>American Journal of Ophthalmology</i> , 2020, 220, 110-114.	3.3	48
141	LGI1 antibody encephalitis: acute treatment comparisons and outcome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 309-315.	1.9	48
142	A mouse model of seizures in anti-N-methyl-D-aspartate receptor encephalitis. <i>Epilepsia</i> , 2019, 60, 452-463.	5.1	46
143	CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1071-1080.	2.3	45
144	Psychiatric Autoimmunity: N-Methyl-d-Aspartate Receptor IgG and Beyond. <i>Psychosomatics</i> , 2015, 56, 227-241.	2.5	44

#	ARTICLE	IF	CITATIONS
145	Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 177-188.	1.9	44
146	Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG. <i>Neurology</i> , 2019, 93, e954-e963.	1.1	43
147	Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability. <i>Epilepsia</i> , 2019, 60, 367-369.	5.1	43
148	GABA _A receptor autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e552.	6.0	42
149	Neuroimmune disorders of the central nervous system in children in the molecular era. <i>Nature Reviews Neurology</i> , 2018, 14, 433-445.	10.1	41
150	Amphiphysin-IgG autoimmune neuropathy. <i>Neurology</i> , 2019, 93, e1873-e1880.	1.1	41
151	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. <i>Clinical Chemistry</i> , 2020, 66, 1496-1509.	3.2	41
152	High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable phage display. <i>Brain Communications</i> , 2020, 2, fcaa059.	3.3	41
153	Reversible Myelopathy in a 34-Year-Old Man With Vitamin B12 Deficiency. <i>Mayo Clinic Proceedings</i> , 2002, 77, 291-294.	3.0	39
154	Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. <i>JAMA Neurology</i> , 2022, 79, 518.	9.0	39
155	Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2017, 74, 359.	9.0	38
156	Autoimmune septin-5 cerebellar ataxia. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e474.	6.0	38
157	Psychiatric Manifestations of Voltage-Gated Potassium-Channel Complex Autoimmunity. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 425-433.	1.8	37
158	OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103525.	2.0	36
159	IMMUNOTHERAPY-RESPONSIVE DEMENTIAS AND ENCEPHALOPATHIES. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2010, 16, 80-101.	0.8	35
160	Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1808-1817.	3.0	35
161	Elevated $\text{LGI} \times \text{IgG} \times \text{CSF}$ index predicts worse neurological outcome. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 646-650.	3.7	35
162	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101487.	2.0	35

#	ARTICLE	IF	CITATIONS
163	Heterogeneity of presentation and outcome in the Irish rapid-onset dystoniaâ€“Parkinsonism kindred. Movement Disorders, 2007, 22, 1325-1327.	3.9	34
164	Striational antibodies in a paraneoplastic context. Muscle and Nerve, 2013, 47, 585-587.	2.2	33
165	Age is a critical determinant in recovery from multiple sclerosis relapses. Multiple Sclerosis Journal, 2019, 25, 1754-1763.	3.0	33
166	Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Multiple Sclerosis Journal, 2022, 28, 480-486.	3.0	32
167	Neuromyelitis Optica: A New Perspective. Seminars in Neurology, 2008, 28, 095-104.	1.4	31
168	Peripherin-IgG association with neurologic and endocrine autoimmunity. Journal of Autoimmunity, 2010, 34, 469-477.	6.5	31
169	Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Communications, 2021, 3, fcaa233.	3.3	31
170	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgGâ€“associated disorders (MOGAD)? Neurology, 2020, 94, 85-88.	1.1	30
171	ITPR1 autoimmunity: Frequency, neurologic phenotype, and cancer association. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e418.	6.0	29
172	MOG-IgG1 and co-existence of neuronal autoantibodies. Multiple Sclerosis Journal, 2021, 27, 1175-1186.	3.0	29
173	Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	29
174	Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations. Mayo Clinic Proceedings, 2022, 97, 547-559.	3.0	29
175	Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	29
176	OKT3 neurotoxicity presenting as akinetic mutism. Transplantation, 2003, 75, 1058-1060.	1.0	28
177	Neurochondrin neurological autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	28
178	Reversible Extralimbic Paraneoplastic Encephalopathies With Large Abnormalities on Magnetic Resonance Images. Archives of Neurology, 2009, 66, 268-71.	4.5	27
179	Autoantibody-Associated Central Nervous System Neurologic Disorders. Seminars in Neurology, 2016, 36, 382-396.	1.4	27
180	Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker. Annals of Neurology, 2021, 89, 1001-1010.	5.3	27

#	ARTICLE	IF	CITATIONS
181	Antiepileptic drug therapy in autoimmune epilepsy associated with antibodies targeting the leucine-rich glioma-inactivated protein 1. <i>Epilepsia Open</i> , 2018, 3, 348-356.	2.4	26
182	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. <i>Neurology</i> , 2019, 93, e414-e420.	1.1	26
183	CRMP5-IgG-Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy. <i>JAMA Neurology</i> , 2020, 77, 255.	9.0	26
184	Paraneoplastic Myeloneuropathies. <i>Neurology</i> , 2021, 96, e632-e639.	1.1	26
185	Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102641.	2.0	26
186	Collapsin Response-Mediator Protein 5-Associated Retinitis, Vitritis, and Optic Disc Edema. <i>Ophthalmology</i> , 2020, 127, 221-229.	5.2	25
187	Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 328-330.	1.9	25
188	Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 630-635.	3.0	25
189	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. <i>Neurology</i> , 2021, 97, e1351-e1358.	1.1	25
190	Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1299-1304.	3.0	24
191	Posttransplant autoimmune encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e497.	6.0	24
192	Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder. <i>Multiple Sclerosis Journal</i> , 2022, 28, 149-153.	3.0	24
193	Diagnostic utility of NMO/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients. <i>Journal of the Neurological Sciences</i> , 2012, 320, 118-120.	0.6	23
194	Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol. <i>Annals of Neurology</i> , 2012, 71, 417-426.	5.3	23
195	GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 55.	2.7	23
196	Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2018-320243.	1.9	23
197	Hydrocephalus in neuromyelitis optica. <i>Neurology</i> , 2014, 82, 1841-1843.	1.1	22
198	Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis. <i>Neuro-Ophthalmology</i> , 2020, 44, 1-4.	1.0	22

#	ARTICLE	IF	CITATIONS
199	Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR. PLoS ONE, 2020, 15, e0242049.	2.5	22
200	Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy. Neurology: Clinical Practice, 2015, 5, 175-177.	1.6	21
201	Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder. Neurology and Therapy, 2022, 11, 123-135.	3.2	21
202	Paraneoplastic and idiopathic autoimmune neurologic disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 165-183.	1.8	20
203	Clinicalâ€pathologic correlations in voltageâ€gated Kv1 potassium channel complexâ€subtyped autoimmune painful polyneuropathy. Muscle and Nerve, 2017, 55, 520-525.	2.2	20
204	MRI findings in glutamic acid decarboxylase associated autoimmune epilepsy. Neuroradiology, 2018, 60, 239-245.	2.2	20
205	Breast cancer-related paraneoplastic neurologic disease. Breast Cancer Research and Treatment, 2018, 167, 771-778.	2.5	20
206	Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. Multiple Sclerosis and Related Disorders, 2021, 47, 102638.	2.0	20
207	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	20
208	Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 196-200.	1.9	20
209	Longitudinal Retinal Changes in <sc>MOGAD</sc>. Annals of Neurology, 2022, 92, 476-485.	5.3	20
210	Neuromyelitis optica and the evolving spectrum of autoimmune aquaporinâ€4 channelopathies. Clinical and Experimental Neuroimmunology, 2014, 5, 175-187.	1.0	18
211	Clinical Utility of Antiretinal Antibody Testing. JAMA Ophthalmology, 2021, 139, 658.	2.5	18
212	Spectrum of sublytic astrocytopathy in neuromyelitis optica. Brain, 2022, 145, 1379-1390.	7.6	18
213	Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. JAMA Neurology, 2018, 75, 892.	9.0	17
214	Neurofascin-155 Immunoglobulin Subtypes. Neurology, 2021, 97, .	1.1	17
215	<sc>Antiâ€Neuronal</sc> Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1. Annals of Neurology, 2022, 91, 670-675.	5.3	17
216	CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. Mayo Clinic Proceedings, 2022, 97, 738-751.	3.0	17

#	ARTICLE	IF	CITATIONS
217	Introduction to autoimmune neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 3-14.	1.8	16
218	Purkinje cell cytoplasmic antibody type I (anti-Yo): predictive of gastrointestinal adenocarcinomas in men. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1116-1117.	1.9	16
219	SMART syndrome: retrospective review of a rare delayed complication of radiation. European Journal of Neurology, 2021, 28, 1316-1323.	3.3	16
220	AQP4-IgG-seronegative patient outcomes in the N-MOMentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2022, 57, 103356.	2.0	16
221	Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers. Annals of Clinical and Translational Neurology, 2021, 8, 425-439.	3.7	16
222	Contactin-1 autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e771.	6.0	15
223	Use of diffusion-weighted imaging to distinguish seizure-related change from limbic encephalitis. Journal of Neurology, 2020, 267, 3337-3342.	3.6	15
224	Seizures and memory impairment induced by patient-derived anti- α -N-methyl-D-aspartate receptor antibodies in mice are attenuated by anakinra, an interleukin-1 receptor antagonist. Epilepsia, 2021, 62, 671-682.	5.1	15
225	Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders. JAMA Neurology, 2020, 77, 1572.	9.0	14
226	Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm. Neurology, 2020, 95, e3002-e3011.	1.1	14
227	GFAP IgG associated inflammatory polyneuropathy. Journal of Neuroimmunology, 2020, 343, 577233.	2.3	14
228	Paraneoplastic cochleovestibulopathy: clinical presentations, oncological and serological associations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1181-1185.	1.9	14
229	CASPR2-IgG-associated autoimmune seizures. Epilepsia, 2022, 63, 709-722.	5.1	14
230	Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity. Epilepsia, 2021, 62, e76-e81.	5.1	13
231	Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 112-114.	1.9	13
232	Autoimmune Neurology of the Central Nervous System. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 627-653.	0.8	13
233	Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	13
234	Interferon beta in multiple sclerosis: how much BENEFIT?. Lancet, The, 2007, 370, 363-364.	13.7	12

#	ARTICLE	IF	CITATIONS
235	Neural Autoantibody Evaluation in Functional Gastrointestinal Disorders: A Population-Based Caseâ€“Control Study. Digestive Diseases and Sciences, 2011, 56, 1452-1459.	2.3	12
236	NMDA receptor encephalitis causing reversible caudate changes on MRI and PET imaging. Neurology: Clinical Practice, 2014, 4, 470-473.	1.6	12
237	Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM. Muscle and Nerve, 2018, 57, 1000-1005.	2.2	12
238	<scp>GTPase</scp> Regulator Associated with Focal Adhesion Kinase 1 (<scp>GRAF1</scp>) <scp>Immunoglobulin</scp>â€“Associated Ataxia and Neuropathy. Movement Disorders Clinical Practice, 2020, 7, 904-909.	1.5	11
239	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110526.	1.0	11
240	NMO spectrum disorders: clinical or molecular classification?. Nature Reviews Neurology, 2016, 12, 129-130.	10.1	10
241	B-cellâ€“targeted therapies in relapsing forms of MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e405.	6.0	10
242	Episodic ataxia in CASPR2 autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e536.	6.0	10
243	Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults. JAMA Neurology, 2022, 79, 808.	9.0	10
244	Individualized Rituximab Treatment for Neuromyelitis Optica Spectrum Disorders. JAMA Neurology, 2013, 70, 1102.	9.0	9
245	Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis. Stroke, 2021, 52, 645-654.	2.0	9
246	Autoimmune gastrointestinal dysmotility following SARSâ€“CoVâ€“2 infection successfully treated with intravenous immunoglobulin. Neurogastroenterology and Motility, 2022, 34, e14314.	3.0	9
247	The orpington prognostic scale within the first 48 hours of admission as a predictor of outcome in ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 2003, 12, 175-181.	1.6	8
248	Autoimmune Myelopathies. CONTINUUM Lifelong Learning in Neurology, 2011, 17, 776-799.	0.8	8
249	Signal recognition particle immunoglobulin g detected incidentally associates with autoimmune myopathy. Muscle and Nerve, 2016, 53, 925-932.	2.2	8
250	Response to: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. CNS Spectrums, 2021, 26, 195-196.	1.2	8
251	MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study. JAMA Ophthalmology, 2021, 139, 583.	2.5	8
252	Neuromyelitis optica spectrum initially diagnosed as antiphospholipid antibody myelitis. Journal of the Neurological Sciences, 2016, 361, 204-205.	0.6	7

#	ARTICLE	IF	CITATIONS
253	Calcium channel autoimmunity: Cerebellar ataxia and Lambert-Eaton syndrome coexisting. Muscle and Nerve, 2018, 58, 29-35.	2.2	7
254	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. Multiple Sclerosis Journal, 2021, 27, 667-673.	3.0	7
255	Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels. Neurology, 2021, , 10.1212/WNL.00000000000012050.	1.1	7
256	Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Multiple Sclerosis and Related Disorders, 2021, 50, 102849.	2.0	7
257	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. Multiple Sclerosis and Related Disorders, 2021, 53, 103080.	2.0	7
258	Exposure to TNF inhibitors is rare at MOGAD presentation. Journal of the Neurological Sciences, 2022, 432, 120044.	0.6	7
259	Uncertain BENEFIT of early interferon beta-1b treatment. Lancet Neurology, The, 2009, 8, 970-971.	10.2	6
260	Monitoring oligoclonal immunoglobulins in cerebral spinal fluid using microLC-ESI-Q-TOF mass spectrometry. Journal of Neuroimmunology, 2015, 288, 123-126.	2.3	6
261	Population-based study of "no evident disease activity" in MS. Neurology: Neuroimmunology and Neuroinflammation, 2018, 5, e495.	6.0	6
262	Paraneoplastic neurological syndrome: an evolving story. Neuro-Oncology Practice, 2021, 8, 362-374.	1.6	5
263	Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation. Rheumatology, 2022, 62, 281-289.	1.9	5
264	Investigating the Immunopathogenic Mechanisms Underlying <scp>MOGAD</scp>. Annals of Neurology, 2022, 91, 299-300.	5.3	5
265	Do not treat from CIS onset: evaluate disease course and prognosis first " Yes. Multiple Sclerosis Journal, 2012, 18, 391-393.	3.0	4
266	Current and future immunotherapy targets in autoimmune neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 511-536.	1.8	4
267	IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 324-326.	1.9	4
268	Autoimmune psychosis. Lancet Psychiatry,the, 2020, 7, 122.	7.4	4
269	Adenylate kinase 5 (AK5) autoimmune encephalitis: Clinical presentations and outcomes in three new patients. Journal of Neuroimmunology, 2022, 367, 577861.	2.3	4
270	Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics, 2022, 19, 711-728.	4.4	4

#	ARTICLE	IF	CITATIONS
271	IgIV-Spectrin Autoantibodies in 2 Individuals With Neuropathy of Possible Paraneoplastic Origin. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	4
272	Clinical Reasoning: A 55-year-old man with weight loss, ataxia, and foot drop. <i>Neurology</i> , 2014, 82, e214-9.	1.1	3
273	Rituximab Therapy in Neuromyelitis Optica. <i>JAMA Neurology</i> , 2015, 72, 974.	9.0	3
274	Dacrystic seizures: A cry for help. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e372.	6.0	3
275	Reader response: Unintended consequences of Mayo paraneoplastic evaluations. <i>Neurology</i> , 2019, 93, 606-606.	1.1	3
276	Polymyoclonus, Laryngospasm, and Cerebellar Ataxia Associated With Adenocarcinoma and Multiple Neural Cation Channel Autoantibodies. <i>Archives of Neurology</i> , 2009, 66, 1285-7.	4.5	2
277	Antibodies to AQP4. , 2014, , 605-611.		2
278	A comparison of tissue-based and recombinant protein-based assays for detecting PCA-Tr/DNER-IgG. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e294.	6.0	2
279	Testing for Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG) in typical MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 34-35.	2.0	2
280	Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e620.	6.0	2
281	Synaptic autoimmunity: new insights into LGI1 antibody-mediated neuronal dysfunction. <i>Brain</i> , 2020, 143, 1622-1625.	7.6	2
282	A Response to: Letter to the Editor Regarding "Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 ImmunoglobulinA-positive Neuromyelitis Optica Spectrum Disorder". <i>Neurology and Therapy</i> , 2022, 11, 1445-1449.	3.2	2
283	Bright red nuclei. <i>Neurology</i> , 2004, 62, 619-619.	1.1	1
284	STIFF EYES IN STIFF-PERSON SYNDROME. <i>Neurology</i> , 2009, 72, 1877-1878.	1.1	1
285	Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders. , 0, , 614-631.		0
286	Reply: A new case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) with initial normal magnetic resonance imaging. <i>Brain</i> , 2011, 134, e183-e183.	7.6	0
287	Autoimmune and Paraneoplastic Neurological Disorders. , 2015, , 467-496.		0
288	PRES leading to the diagnosis of McArdle disease. <i>Journal of Clinical Neuroscience</i> , 2017, 46, 62-64.	1.5	0

#	ARTICLE	IF	CITATIONS
289	Paraneoplastic Neurologic Disease. , 2019, , 141-157.		0